yemenjmedYemen Journal of MedicinecoVolume 4 Issue 1MultidisciplinaryEnglishJanuary- April 2025NNY20250521ArticleCardiorenal, Renocardiac, and Reno-Cardio-Cardiac Syndromes: An Updated Review on  General Definitions, Pathophysiology, and Therapies (Part 1)EnglishY942ElmukhtarHabas1EnglishNAlaHabas2EnglishYAmnnaRayani3EnglishYAmlHabas4EnglishYGamalAlfitori5EnglishYEshrakHabas2EnglishYAlmehdiErrayes5EnglishYKalifaFarfar6EnglishYAnandKartha5EnglishYAbdel-NaserElzouki5EnglishY10.63475/yjm.v4i1.0028Background: Acute and chronic heart or kidney failure affect each other in cardiorenal syndromes (CRS). In CRS, hemodynamic and non-hemodynamic changes occur, causing acute or progressive renal and cardiac failures. CRS is classified into five types based on the first organ failure and causes failure of the other organ. We believe that the current CRS classification is not the correct one that effectively describes the underlying cause of CRS. Hence, we consider it better to be classified into three categories (cardiorenal, renocardiac, and cardio-reno-cardiac syndrome) and then subdivided into acute and chronic types or types 1 and 2 (respectively, according to the onset of the underlying type of failure (i.e., acute or chronic). Other subtypes that occur in the heart and dysfunction occur simultaneously are acute cardio-reno-cardiac syndrome (type 5) and Chronic cardio-reno-cardiac syndrome (type 6).  Aim: In Part 1 of the review series, the pathophysiological mechanisms and clinical and therapeutic applications of all types of CRS will be narratively discussed and updated. Furthermore, we provide a comprehensive review of diagnostic biomarkers and their clinical significance in the identification, outcome prediction, and treatment of all CRS types.  Method: An extensive search of PubMed, Google, EMBASE, Scopus, and Google Scholar was conducted for review articles, original articles, and commentaries published between Jan 2010 and Aug 2024 using different phrases, texts, and keywords, such as CRS, renocardiac syndrome, and CRS. The topics included secondary CRS, CRS pathogenesis, CRS therapy, SLGT inhibitor use in CRS, novel therapy in CRS types, and prevention of CRSs.  Conclusion: Renal and cardiac failure in patients with CRS seem to have different pathophysiological mechanisms. Early detection and treatment can improve the outcomes of CRS. Clinical manifestations and therapy protocols vary according to pathophysiology. Hence, new guidelines and research on universal diagnostic and treatment techniques are urgently required. Moreover, the current nomenclature for CRS is confusing; therefore, we believe that a new nomenclature system should be introduced, reducing confusion and making differentiation between CRS types easier and less confusing.  EnglishChronic kidney disease, acute decompensated heart failure, Cardiorenal syndrome, Renocardiac syndromehttps://www.yemenjmed.com/admin/abstract?id=131References1619Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al.and;nbsp;Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2010;165:54-67.Forman DE, Butler J, Wang Y, Abraham WT, Oand;#39;Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-7.Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9:195-201.Goffredo G, Barone R, Di Terlizzi V, Correale M, Brunetti ND, Iacoviello M. Biomarkers in cardiorenal syndrome. J Clin Med. 2021;10:3433.House AA, Anand I, Bellomo R, Cruz D, Bobek I, Anker SD, Aspromonte N, et al. Definition and classification of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant. 2010;25:1416-20.Ajibowo AO, Okobi OE, Emore E, Soladoye E, Sike CG, Odoma VA, et al. Cardiorenal Syndrome: A Literature Review. Cureus. 2023;15(7): e41252.Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527-39.Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-8.Thind GS, Loehrke M, Wilt JL. Acute cardiorenal syndrome: Mechanisms and clinical implications. Cleve Clin J Med. 2018;85(3):231-9.Habas El, Akbar R, Khan F, Elzouki AN. Reno-Cardiac Syndrome (RCS): A Clinical Review. IJSR. 2021;10(6): 1705-1712.Kumar U, Wettersten N, Garimella PS. Cardiorenal Syndrome: Pathophysiology. Cardiol Clin. 2019;37(3):251-5.Zhang Y, Jiang Y, Yang W, Shen L, He B. Chronic Secondary Cardiorenal Syndrome: The Sixth Innovative Subtype. Front Cardiovasc Med. 2021;8639959.Chang CH, Lin CY, Tian YC, Jenq CC, Chang MY, Chen YC, et al. Acute kidney injury classification: comparison of AKIN and RIFLE criteria. Shock. 2010;33(3):247-52.Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, et al. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol. 2013;9(2):99-111.Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16):e840-e878.Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422-30.Hakahama H, Kitakaze M. Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. Am J Physiol Heart Circ Physiol. 2017 ;313(4):715-21.Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8(3):136-41.Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J. 2005;150(2):330-7.Newsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med. 2008;168(6):609.Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med. 2008;168(9):987-95.Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006;17(10):2886-91.Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268-74.Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RI. Correlates and impact on outcomes of worsening renal function in patients and;gt; or =65 years of age with heart failure. Am J Cardiol. 2000;85(9):1110-3.Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9(1):13-25.Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589-596.Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007;99(3):393-8.Dimopoulos K, Diller GP, Koltsida E, Pijuan-Domenech A, Papadopoulou SA, Babu-Narayan SV, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2008;117(18):2320-8.Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care. 2002;8:509and;ndash;14.Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial. JAMA. 2005;294(3):342-50.Leacche M, Rawn JD, Mihaljevic T, Lin J, Karavas AN, Paul S, Byrne JG. Outcomes in patients with normal serum creatinine and with artificial renal support for acute renal failure developing after coronary artery bypass grafting. Am J Cardiol. 2004;93(3):353-6.Bove T, Calabrand;ograve; MG, Landoni G, Aletti G, Marino G, Crescenzi G, Rosica C, et al. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth. 2004;18(4):442-5.Hoste EA, Cruz DN, Davenport A, Mehta RL, Piccinni P, Tetta C, et al. The epidemiology of cardiac surgery-associated acute kidney injury. Int J Artif Organs. 2008;31(2):158-65.Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004;65(6):2380-9.Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35(3):681-9.Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489-95.Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006 ;113(5):671-8.McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11;167(11):1122-9.Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799-805.Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int. 2007;11(1):1-14.Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999and;ndash;2004. Am J Kidney Dis. 2008 Apr;51(4 Suppl 2):S38-45.McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug;156(2):277-83.Mahon NG, Blackstone EH, Francis GS, Starling RC 3rd, Young JB, Lauer MS. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;40:1106and;ndash;13.Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745-53.Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10.Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-54.Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28:108and;ndash;121.Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 2009;35(5):871-81.Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, et al. Acute renal failure in patients with sepsis. Crit Care. 2007;11(2):411.Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care. 2008;12(2):R47.Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, et al. Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant. 2008;23(3):904-9.Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. 2004;32(3):660-5.Jardin F, Fourme T, Page B, Loubiand;egrave;res Y, Vieillard-Baron A, Beauchet A, et al. Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. Chest. 1999;116(5):1354-9.ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, et al. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem. 2000;46(5):650-7.Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med. 2000 Jan;26(1):31-7.Mehta NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR.and;nbsp;Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004;95(1):13-7.Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka HI, Oechslin E, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003 Jun 4;41(11):2004-9.Georgopoulou T, Petrakis I, Dermitzaki K, Pleros C, Drosataki E, et al. Cardiorenal Syndrome: Challenges in Everyday Clinical Practice and Key Points towards a Better Management. J Clin Med. 2023;12(12):4121.Kim CJ, Choi IJ, Park HJ, Kim TH, Kim PJ, Chang K, et al. Impact of Cardiorenal Anemia Syndrome on Short- and Long-Term Clinical Outcomes in Patients Hospitalized with Heart Failure. Cardiorenal Med. 2016;6(4):269-78.Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35(7)1737-44Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52(10):818-27.Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. Relation of Low Hemoglobin and Anemia to Morbidity and Mortality in Patients Hospitalized With Heart Failure (Insight from the OPTIMIZE-HF Registry). The American Journal of Cardiology 2008;101(2):223-30.Palazzuoli A, Antonelli G, Nuti R. Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. Heart Fail Rev 2011;16(6):603-7.Adams KF Jr, Patterson JH, Oren RM, Mehra MR, Oand;#39;Connor CM, Piand;ntilde;a IL, et al. Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. American Heart Journal 2009;157(5):926-32.van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008;4(1):47-57.Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010;121(2):245-51.Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev. 2008;13(4):393-404. doi: 10.1007/s10741-008-9086-x.KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006 ;47(5 Suppl 3):S11-145.Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol. 2000;53(1):S18-22.Brezis M, Rosen S. Hypoxia of the Renal Medulla and;mdash; Its Implications for Disease. New England Journal of Medicine 1995;332(10):647and;ndash;655.Denton KM, Shweta A, Anderson WP. Preglomerular and Postglomerular Resistance Responses to Different Levels of Sympathetic Activation by Hypoxia. JASN 2002;13(1):27-34.Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M,and;nbsp;et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. New England Journal of Medicine 2006;355(20):2085and;ndash;2098.Drand;uuml;eke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU,and;nbsp;et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. New England Journal of Medicine 2006;355(20):2071and;ndash;2084.Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine 2009;361(21):2019-32.Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R,and;nbsp;et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine 2013;368(13):1210-9.McCullough PA. Anemia of cardiorenal syndrome. Kidney Int Suppl (2011). 2021;11(1):35-45.House AA, Wanner C, Sarnak MJ, Piand;ntilde;a IL, McIntyre CW, Komenda P,and;nbsp;et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 Jun;95(6):1304-1317.Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Land;uuml;scher T,and;nbsp;et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail. 2015;17(3):329-39.Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M,and;nbsp;et al. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023;104(4):655-680.Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H,et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.Ben-Assa E, Shacham Y, Shashar M, Leshem-Rubinow E, Gal-Oz A, Schwartz IF,and;nbsp;et al. Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study. Cardiorenal Med. 2015;5(4):246-53.Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R,and;nbsp;et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 ;368(13):1210-9.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ,and;nbsp;et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution . Eur J Hear Fail 2016;18(8)891-975.Locatelli F, Del Vecchio L, Esposito C, et al. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease. J Nephrol. 2024.Locatelli F, Band;aacute;rand;aacute;ny P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D,and;nbsp;et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346-59.Jackevicius CA, Co MJ, Warner AL. Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome. Int J Pharm Pract. 2015;23(3):199-204.Kaplan JM, Sharma N, Dikdan S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. Int J Mol Sci. 2018;19(2):389.Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677-84.Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R,and;nbsp;et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001;15:80-6.Glance LG, Wissler R, Mukamel DB, Li Y, Diachun CA, Salloum R, et al. Perioperative outcomes among patients with the modified metabolic syndrome who are undergoing noncardiac surgery. Anesthesiology. 2010, 113:859-72.Scabbia EV, Scabbia L. The cardio-renal syndrome (CRS). IJC Metab Endoc. 2015;9:1-4. http://creativecommons.org/licenses/by-nc-nd/3.0/. Accessed May 2024.Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22(1)195.Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB,and;nbsp;et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pr 2022;183109119.Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356.GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-33.Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N,and;nbsp;et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Hear J. 2018;39(48)4243-4254.Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Hear Fail 2018;20(5)853-872.Usman MS, Khan MS, Butler J. The Interplay Between Diabetes, Cardiovascular Disease, and Kidney Disease. 2021. In: Chronic Kidney Disease and Type 2 Diabetes. Arlington (VA): American Diabetes Association; 2021. Bookshelf ID NBK571718.Damman K, Valente MA, Voors AA, Oand;#39;Connor CM, van Veldhuisen DJ, Hillege HL. et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Hear J. 2014;35(7)455-69.Jankowski J, Floege J, Fliser D, Band;ouml;hm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circ 2021;143(11)1157-1172.Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121(23):2592-600.Burke M, Pabbidi MR, Farley J, Roman RJ.and;nbsp;Molecular mechanisms of renal blood flow autoregulation. Curr Vasc Pharmacol. 2014;12(6):845-58.Hanberg JS, Sury K, Wilson FP, Brisco MA, Ahmad T, Ter Maaten JM, et al. Reduced Cardiac Index Is Not the Dominant Driver of Renal Dysfunction in Heart Failure. J Am Coll Cardiol. 2016;67(19):2199-208.Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH).Eur Heart J. 2006;27(10):1216and;ndash;22.Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM,and;nbsp;et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147(2):331-8.Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138(2):285-90.Grams ME, Astor BC, Bash LD, Matsushita K, Wang Y, Coresh J.and;nbsp;Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J Am Soc Nephrol. 2010;21(10):1757-64.Sowers JR, Whaley-Connell A, Hayden MR. The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med. 2011;1(1):5-12.Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol. 2012;60(12):1031-42.Hunley TE, Ma LJ, Kon V. Scope and mechanisms of obesity-related renal disease. Curr Opin Nephrol Hypertens. 2010;19(3):227-34.Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, Vatten LJ.and;nbsp;Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. Circulation. 2016;133(7):639-49.Uduman J. Epidemiology of Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018;25(5):391-9.Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B,and;nbsp;et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol. 2012;60(20):2082-9.Palazzuoli A, Testani JM, Ruocco G, Pellegrini M, Ronco C, Nuti R.and;nbsp;Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance. Int J Cardiol. 2016;224:213-9. doi: 10.1016/j.ijcard.2016.09.005.Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. N Engl J Med. 2017;377(20):1964-1975.Hostetter TH, Pfeffer JM, Pfeffer MA, Dworkin LD, Braunwald E, Brenner BM. Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 1983;245(1):H98and;ndash;H103.Binanay C, Califf RM, Hasselblad V, Oand;#39;Connor CM, Shah MR, Sopko G, et al; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294(13):1625and;ndash;1633.Tarvasmand;auml;ki T, Haapio M, Mebazaa A, Sionis A, Silva-Cardoso J, Tolppanen H,and;nbsp; et al. Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality. European Journal of Heart Failure 2018;20(3):572and;ndash;581.Lauschke A, Teichgrand;auml;ber UKM, Frei U, Eckardt K-U. and;lsquo;Low-doseand;rsquo; dopamine worsens renal perfusion in patients with acute renal failure. Kidney International 2006;69(9):1669and;ndash;1674.Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease. Journal of the American College of Cardiology 2009;53(7):582and;ndash;588.Dalfino L, Tullo L, Donadio I, Malcangi V, Brienza N. Intra-abdominal hypertension and acute renal failure in critically ill patients. Intensive Care Med. 2008;34(4):707-13.Damman K, Valente MAE, van Veldhuisen DJ, Cleland JGF, Oand;#39;Connor CM, Metra M,et al. Plasma neutrophil gelatinase-associated lipocalin and predicting clinically relevant worsening renal function in acute heart failure. Int J Mol Sci. 2017; 18(7):1470.Burnett JC Jr, Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol. 1980, 238:F279-82.Afsar B, Ortiz A, Covic A, Solak Y, Goldsmith D, Kanbay M.and;nbsp;Focus on renal congestion in heart failure. Clin Kidney J. 2016;9(1):39-47.Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WH, Mullens W. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 2013;62(6):485-95.Alpert JS. The effect of right ventricular dysfunction on left ventricular form and function. Chest 2001;119(6)1632-3.Konstam, MA, Isner, J. The Right Ventricle, Konstam, MA, Isner, J (Eds), Kluwer Academic Publishers, 2009.Marcus JT, Vonk Noordegraaf A, Roeleveld RJ, Postmus PE, Heethaar RM, Van Rossum AC,and;nbsp;et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest 2001;119(6)1761-5.Little WC, Badke FR, Oand;#39;Rourke RA. Effect of right ventricular pressure on the end-diastolic left ventricular pressure-volume relationship before and after chronic right ventricular pressure overload in dogs without pericardia. Circ Res 1984;54(6)719-30.Testani JM, Khera AV, St John Sutton MG, Keane MG, Wiegers SE, Shannon RP, et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010; ;105(4)511-6.Chinnappa S, Tu Y-K, Yeh YC, Glorieux G, Vanholder R, Mooney A. Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease. Toxins (Basel) 2018;10(12).Lin CJ, Liu HL, Pan CF, Chuang CK, Jayakumar T, Wang TJ, Chen HH,and;nbsp;et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res 2012;43(6):451and;ndash;456.Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ,and;nbsp;et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011;26(3):938and;ndash;947.Dand;#39;Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A,and;nbsp;et al. The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. Oxid Med Cell Longev. 2020;2020:5732956.Owada S, Goto S, Bannai K, Hayashi H, Nishijima F, Niwa T. Indoxyl Sulfate Reduces Superoxide Scavenging Activity in the Kidneys of Normal and Uremic Rats. AJN 2008;28(3):446and;ndash;454.Lekawanvijit S, Krum H. Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins. J Physiol 2014;592(Pt 18):3969and;ndash;3983.Dand;#39;Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A, et al. Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. CJASN 2009;4(10):1551-8.Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T,and;nbsp;et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121(11):4393and;ndash;4408.Reddy SSK, Chaiban JT. THE ENDOCRINOLOGY OF AGING: A KEY TO LONGEVITY and;ldquo;GREAT EXPECTATIONSand;rdquo;. Endocr Pract. 2017;23(9):1107-1116.Donovan K, Herrington WG, Parand;eacute; G, Pigeyre M, Haynes R, Sardell R, et al. Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study. Clin J Am Soc Nephrol. 2023;18(1)17-27.Kao YH, Chen YC, Lin YK, Shiu RJ, Chao TF, Chen SA, Chen YJ. FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells. Eur J Clin Invest 2014;44(8):795and;ndash;801.Lewiecki EM, Bilezikian JP, Khosla S, Marcus R, McClung MR, Miller PD,and;nbsp;et al. Osteoporosis update from the 2010 santa fe bone symposium. J Clin Densitom. 2011;14(1)1-21.Borovac JA, Dand;#39;Amario D, Bozic J, Glavas D.and;nbsp;Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers. World J Cardiol. 2020;12(8):373-408.Floras JS, Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J. 2015;36(30):1974-82b.Heesch CM. Reflexes that control cardiovascular function. Am J Physiol. 1999;277(6):234-43.Kopp UC. Neural Control of Renin Secretion Rate Morgan and;amp; Claypool Life Sciences; 2011. https://www.ncbi.nlm.nih.gov/books/NBK57240/. Accessed April, 2024.de Lucia C, Piedepalumbo M, Paolisso G, Koch WJ. Sympathetic nervous system in age-related cardiovascular dysfunction: Pathophysiology and therapeutic perspective. Int J Biochem Cell Biol. 2019;108:29-33.Zhang DY, Anderson AS. The sympathetic nervous system and heart failure. Cardiol Clin. 2014;32(1):33-45.riposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J.and;nbsp;The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747-62.Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747-62.Feng QP, Hedner T, Andersson B, Lundberg JM, Waagstein F. Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J. 1994;71(3):261-7.Herring N, Cranley J, Lokale MN, Li D, Shanks J, Alston EN,and;nbsp;et al. The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability. J Mol Cell Cardiol. 2012;52(3):667-76.Herring N, Cranley J, Lokale MN, Li D, Shanks J, Alston EN, et al. Contribution of the endothelin system to the renal hypoperfusion associated with experimental congestive heart failure. J Cardiovasc Pharmacol. 1999;34(4):612-7.Mahata SK, Oand;#39;Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H,and;nbsp;et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest. 1997;100(6):1623-33.Ahmad Y, Francis DP, Bhatt DL, Howard JP.and;nbsp;Renal Denervation for Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials. JACC Cardiovasc Interv. 2021;14(23):2614-2624.Roubsanthisuk W, Kunanon S, Chattranukulchai P, Panchavinnin P, Wongpraparut N, Chaipromprasit J, et al. 2022 Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society. Hypertens Res. 2023;46(4)898-912.Kim J, Padanilam BJ. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol. 2013;24(2):229-42.Wills LP, Trager RE, Beeson GC, Lindsey CC, Peterson YK, Beeson CC,and;nbsp;et al. The and;beta;2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis. J Pharmacol Exp Ther. 2012;342(1):106-18.Jesinkey SR, Funk JA, Stallons LJ, Wills LP, Megyesi JK, Beeson CC,and;nbsp;et al. Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury. J Am Soc Nephrol. 2014;25(6):1157-62.Hasegawa S, Inoue T, Nakamura Y, Fukaya D, Uni R, Wu CH,and;nbsp;et al. Activation of Sympathetic Signaling in Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-Reperfusion Injury. J Am Soc Nephrol. 2021;32(7):1599-1615.Doi K, Matsuura R. Sympathetic Nerve Activation in Acute Kidney Injury and Cardiorenal Syndrome. Nephron. 2023;147(12):717-720.Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13(8):599-608.Jois P, Mebazaa A. Cardio-renal syndrome type 2: epidemiology, pathophysiology, and treatment. Semin Nephrol. 2012;32(1):26-30.Matsuura R, Yamashita T, Hayase N, Hamasaki Y, Noiri E, Numata G,and;nbsp;et al. Preexisting heart failure with reduced ejection fraction attenuates renal fibrosis after ischemia reperfusion via sympathetic activation. Sci Rep. 2021;11(1):15091.Harrison-Bernard LM. The renal renin-angiotensin system. Advances in Physiology Education 2009;33(4):270-4.Johnson MD, Malvin RL. Stimulation of renal sodium reabsorption by angiotensin II. Am J Physiol 1977;232(4):298-306.Barton M, Shaw S, dand;#39;Uscio LV, Moreau P, Land;uuml;scher TF.Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun. 1997;238(3):861-5.Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. European Journal of Clinical Investigation 2006;36(s3):78-88.Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-and;beta;1 and endothelin-1 from fibroblasts. Cardiovascular research 1998;40(2):352-63.Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. Curr Opin Cardiol. 2007 Jul;22(4):311-5..Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J.and;nbsp;The Sympathetic Nervous System in Heart Failure: Physiology, Pathophysiology, and Clinical Implications. Journal of the American College of Cardiology 2009;54(19):1747-62. doi: 10.1016/j.jacc.2009.05.015.Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M.and;nbsp;Plasma Adenosine Levels Increase in Patients With Chronic Heart Failure. Circulation 1997;95(6):1363-5.Massie BM, Oand;#39;Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G,and;nbsp;et al. Rolofylline, an Adenosine A1and;minus;Receptor Antagonist, in Acute Heart Failure. New England Journal of Medicine 2010;363(15):1419-28.Torres VE. Vasopressin in chronic kidney disease, an elephant in the room? Kidney Int 2009;76(9):925-28.Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci USA 1999;96(18):10397-402.Rouleau JL, Packer M, Moyand;eacute; L, de Champlain J, Bichet D, Klein M, Rouleau JR, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24(3):583-91.Kazory A, Costanzo MR. The dynamic relationship between serum chloride and cardiorenal syndrome. Rev Cardiovasc Med. 2020;21(1):25-29.Rinehart J, Kahle KT, de Los Heros P, Vazquez N, Meade P, Wilson FH,and;nbsp;et al. WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-Cland;minus; cotransporters required for normal blood pressure homeostasis. Proc Natl Acad Sci USA. 2005;10216777and;ndash;16782.Liang L, Shimosawa T. Molecular Mechanisms of Na-Cl Cotransporter in Relation to Hypertension in Chronic Kidney Disease. Int J Mol Sci. 2022;24(1):286. doi: 10.3390/ijms24010286.Berend K, van Hulsteijn LH, Gans RO. Chloride: the queen of electrolytes? Eur J Intern Med. 2012;23(3):203-11.Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, et al. Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights. Circ Heart Fail. 2016;9(8):1-12.Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, Oand;#39;Connor CM,, et al. Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circ Heart Fail. 2016;9(8):e003109.Kotchen TA, Luke RG, Ott CE, Galla JH, Whitescarver S. Effect of chloride on renin and blood pressure responses to sodium chloride. Ann Intern Med. 1983;98(5 Pt 2):817-22.Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Invest. 1983;71(3):726-35.Cuthbert JJ, Pellicori P, Rigby A, Pan D, Kazmi S, Shah P, et al. Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. Eur J Heart Fail. 2018;20(10):1426-1435.Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M,and;nbsp;et al. Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. J Am Coll Cardiol. 2015;66(6):659-66.Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997;82(2):291-5.Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. American Journal of Physiology-Lung Cellular and Molecular Physiology 2000;279(6):L1005and;ndash;L1028.Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M,and;nbsp;et al. Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect? Curr Heart Fail Rep. 2015;12(3):215-22.Katz AM, Konstam MA. Heart failure: pathophysiology, molecular biology, and clinical management, 2nd edn. Lippincott Williams and;amp; Wilkins, Philadelphia, 2009.Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M,and;nbsp; et al. Role of NAD(P)H oxidase-and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005; 45(5):860-6.Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. Journal of molecular and cellular cardiology 2003; 35(7):851-9.Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol. 1997;8(3):475-86.Kraut EJ, Chen S, Hubbard NE, Erickson KL, Wisner DH. Tumor necrosis factor depresses myocardial contractility in endotoxemic swine. J Trauma. 1999, 46:900-6.Radeke HH, Meier B, Topley N, Fland;ouml;ge J, Habermehl GG, Resch K. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int. 1990;37(2):767-75.Wettersten N, Maisel AS. Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. Am J Med 2016;129(6):560-7.Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C,and;nbsp;et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney International 2010;77(6):550-6.Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M,and;nbsp;et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int 2005;67(4):1216and;ndash;1233.Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA.and;nbsp;Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994;45(3):890-6.Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney International 2001;59(2):407and;ndash;14.Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82(2):513-20.Minami Y, Kajimoto K, Sato N, Hagiwara N; ATTEND Study Investigators. Effect of Elevated C-Reactive Protein Level at Discharge on Long-Term Outcome in Patients Hospitalized for Acute Heart Failure. The American Journal of Cardiology 2018;121(8):961-8.Kim BS, Jeon DS, Shin MJ, Kim YO, Song HC, Lee SH, et al. Persistent Elevation of C-Reactive Protein May Predict Cardiac Hypertrophy and Dysfunction in Patients Maintained on Hemodialysis. AJN 2005;25(3):189-95.Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, et al. Pathophysiology of the cardio-renal syndromes types 1and;ndash;5: An uptodate. Indian Heart Journal 2017;69(2):255-65.Wang CS, FitzGerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294(15):1944-56.Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004;125(2):669-82.Schanz M, Shi J, Wasser C, Alscher MD, Kimmel M. Urinary [TIMP-2] and;times; [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Clin Cardiol. 2017;40(7):485-91.Ahmed MM, Tazyeen S, Alam A, Farooqui A, Ali R, Imam N,and;nbsp;et al. Deciphering key genes in cardio-renal syndrome using network analysis. Bioinformation. 2021;17(1):86-100.Maisel AS, Katz N, Hillege HL, Shaw A, Zanco P, Bellomo R,and;nbsp;et al. Biomarkers in kidney and heart disease. Nephrol Dial Transplant. 2011;26(1):62-74.Oliveros E, Oni ET, Shahzad A, Kluger AY, Lo KB, Rangaswami J, McCullough PA.and;nbsp;Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. Cardiorenal Med. 2020;10(2):69-84.Bouquegneau A, Krzesinski JM, Delanaye P, Cavalier E. Biomarkers and physiopathology in the cardiorenal syndrome. Clin Chim Acta. 2015;443:100-7.Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci. 2011;1243:88-102.Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV,and;nbsp;et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR.and;nbsp;Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients.Clin J Am Soc Nephrol. 2010;5:402and;ndash;408.Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A; NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis.Am J Kidney Dis. 2009; 54:1012-24.Mortara A, Bonadies M, Mazzetti S, Fracchioni I, Delfino P, Chioffi M,and;nbsp;et al. Neutrophil gelatinase-associated lipocalin predicts worsening of renal function in acute heart failure: methodological and clinical issues.J Cardiovasc Med (Hagerstown). 2013; 14:629and;ndash;634.Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M,and;nbsp; et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.Crit Care. 2013; 17:R25.Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1-e167.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e161.McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE,and;nbsp;et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.Am J Kidney Dis. 2003; 41:571and;ndash;579.McCullough PA, Neyou A. Comprehensive review of the relative clinical utility of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide assays in cardiovascular disease.Open Heart Fail J. 2009; 3:6and;ndash;17.Palazzuoli A, Ruocco G, Pellegrini M, Martini S, Del Castillo G, Beltrami M,and;nbsp;et al. Patients with cardiorenal syndrome revealed increased neurohormonal activity, tubular and myocardial damage compared to heart failure patients with preserved renal function.Cardiorenal Med. 2014; 4:257-68.Maisel AS, Daniels LB, Anand IS, McCullough PA, Chow SL. Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.Postgrad Med. 2018; 130:299and;ndash;307.Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL,and;nbsp;et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Clin Res Cardiol. 2010; 99:323and;ndash;328.McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.Rev Cardiovasc Med. 2011; 12:200and;ndash;210.van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.Circ Heart Fail. 2013; 6:219and;ndash;226.Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A, et al. Trial of an Intervention to Improve Acute Heart Failure Outcomes. N Engl J Med. 2023;388(1):22-32.Colbert G, Jain N, de Lemos JA, Hedayati SS. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD.Clin J Am Soc Nephrol. 2015; 10:515and;ndash;529.Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.Circulation. 2006; 114:1572-80.Beigel R, Cercek B, Siegel RJ, Hamilton MA. Echo-Doppler hemodynamics: an important management tool for todayand;rsquo;s heart failure care.Circulation. 2015; 131:1031-4.Cowie B, Kluger R, Rex S, Missant C. Noninvasive estimation of left atrial pressure with transesophageal echocardiography.Ann Card Anaesth. 2015; 18:312and;ndash;316.Mavrakanas TA, Khattak A, Singh K, Charytan DM. Epidemiology and natural history of the cardiorenal syndromes in a cohort with echocardiography.Clin J Am Soc Nephrol. 2017; 12:1624and;ndash;1633.Kramann R, Erpenbeck J, Schneider RK, Rand;ouml;hl AB, Hein M, Brandenburg VM, et al. Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.J Am Soc Nephrol. 2014; 25:2351-65.Hassanin N, Alkemary A. Early detection of subclinical uremic cardiomyopathy using two-dimensional speckle tracking echocardiography.Echocardiography. 2016; 33:527-36.Krishnasamy R, Isbel NM, Hawley CM, et al. The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality.Nephrol Dial Transplant. 2014; 29:1218-25.Iida N, Seo Y, Sai S, Machino-Ohtsuka T, Yamamoto M, Ishizu T, et al. Clinical implications of intrarenal hemodynamic evaluation by Doppler ultrasonography in heart failure.JACC Heart Fail. 2016; 4:674-82.Nijst P, Martens P, Dupont M, Tang WHW, Mullens W. Intrarenal flow alterations during transition from euvolemia to intravascular volume expansion in heart failure patients.JACC Heart Fail. 2017; 5:672-81.Faubel S, Patel NU, Lockhart ME, Cadnapaphornchai MA. Renal relevant radiology: use of ultrasonography in patients with AKI.Clin J Am Soc Nephrol. 2014; 9:382-94.Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance.JACC Cardiovasc Imaging. 2014;7:703and;ndash;714.Rutherford E, Talle MA, Mangion K, Bell E, Rauhalammi SM, Roditi G, et al. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping.Kidney Int. 2016; 90:845-52.Graham-Brown MP, March DS, Churchward DR, Stensel DJ, Singh A, Arnold R, et al. Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients.Kidney Int. 2016; 90:835and;ndash;844.Piccoli A, Codognotto M, Cianci V, Vettore G, Zaninotto M, Plebani M, et al. Differentiation of cardiac and noncardiac dyspnea using bioelectrical impedance vector analysis (BIVA).J Card Fail. 2012; 18:226and;ndash;232.Santarelli S, Russo V, Lalle I, De Berardinis B, Navarin S, Magrini L, et al. Usefulness of combining admission brain natriuretic peptide (BNP) plus hospital discharge bioelectrical impedance vector analysis (BIVA) in predicting 90 days cardiovascular mortality in patients with acute heart faiure.and;nbsp; Intern Emerg Med. 2017;12(4):445-451.Gnanaraj J, Radhakrishnan J. Cardio-renal syndrome. F1000Res. 2016, 5:Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011, 364:797-805.Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, et al. Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant. J Heart Lung Transplant. 2013;32(12):1205-13.Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265-72.Bowman BN, Nawarskas JJ, Anderson JR. Treating Diuretic Resistance: An Overview. Cardiol Rev. 2016;24(5):256-60.Uwai Y, Saito H, Hashimoto Y, Inui KI. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther 2000; 295:261and;ndash;265.Hacker K, Maas R, Kornhuber J, Fromm MF, Zolk O. Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates. PLoS One. 2015;10(9):e0136451.Schophuizen CM, Wilmer MJ, Jansen J, Gustavsson L, Hilgendorf C, Hoenderop JG, et al. Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter. Pflugers Arch. 2013;465(12):1701-14.Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387-95.Grodin JL, Stevens SR, de las Fuentes L, Kiernan M, Birati EY, Gupta D, et al. Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. J Card Fail. 2016;22(1):26-32.Thomson MR, Nappi JM, Dunn SP, Hollis IB, Rodgers JE, Van Bakel AB. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010;16(3):188-93.Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-95.Martens P, Verbrugge FH, Dauw J, Nijst P, Meekers E, Augusto SN, et al. Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial. Eur Heart J. 2023;44(22):1995-2005.Cooper LB, Mentz RJ, Gallup D, Lala A, DeVore AD, Vader JM, AbouEzzeddine OF, et al. Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. J Card Fail. 2016;22(9):738-4.Martens P, Dauw J, Verbrugge FH, Nijst P, Meekers E, Augusto SN Jr, et al. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial. Circulation. 2023;147(3):201-211.Meekers E, Dauw J, Martens P, Dhont S, Verbrugge FH, Nijst P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44(37):3672-82.Dhont S, Martens P, Meekers E, Dauw J, Verbrugge FH, Nijst P, et al. Sodium and potassium changes during decongestion with acetazolamide - a pre-specified analysis from the ADVOR trial. Eur J Heart Fail. 2023; ;25(8):1310-9.Ng TM, Konopka E, Hyderi AF, Hshieh S, Tsuji Y, Kim BJ, et al. Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. J Cardiovasc Pharmacol Ther. 2013;18(4):345-53.Jentzer JC, Chawla LS. A Clinical Approach to the Acute Cardiorenal Syndrome. Crit Care Clin. 2015;31(4):685-703.Sica DA. Metolazone and its role in edema management. Congest Heart Fail. 2003;9(2):100-5.Moranville MP, Choi S, Hogg J, Anderson AS, Rich JD. Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance. Cardiovasc Ther. 2015;33(2):42-9.Steuber TD, Janzen KM, Howard ML. A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure. Pharmacotherapy. 2020;40(9):924-35.Verbrugge FH, Dupont M, Bertrand PB, Nijst P, Penders J, Dens J, Verhaert D, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70(3):265-73.Verbrugge FH, Martens P, Ameloot K, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail. 2019 Nov;21(11):1415-1422.Martens P, Dauw J, Verbrugge FH, Nijst P, Meekers E, Augusto SN Jr, Ter Maaten JM, et al. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial. Circulation. 2023;147(3):201-211.Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950-8.Kabach M, Alkhawam H, Shah S, Joseph G, Donath EM, Moss N, et al. Ultrafiltration versus intravenous loop diuretics in patients with acute decompensated heart failure: a meta-analysis of clinical trials. Acta Cardiol. 2017;72(2):132-41.Pourafshar N, Karimi A, Kazory A. Extracorporeal ultrafiltration therapy for acute decompensated heart failure. Expert Rev Cardiovasc Ther. 2016;14(1):5-13.Grodin JL, Carter S, Bart BA, Goldsmith SR, Drazner MH, Tang WH. Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF. Eur J Heart Fail. 2018;20(7):1148-1156.Bart BA, Goldsmith SR, Lee KL, Givertz MM, Oand;#39;Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-304.Vinod P, Krishnappa V, Chauvin AM, Khare A, Raina R. Heart failure and acute renal dysfunction in the cardiorenal syndrome. Clin Med (Lond). 2020;20(2):146-150.Kazory A. Cardiorenal syndrome: ultrafiltration therapy for heart failure--trials and tribulations. Clin J Am Soc Nephrol. 2013;8(10):1816-28.Ronco C, Giomarelli P. Current and future role of ultrafiltration in CRS. Heart Fail Rev. 2011;16(6):595-602.Chuasuwan A, Kellum JA. Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Semin Nephrol. 2012;32(1):31-9.Vinod P, Krishnappa V, Chauvin AM, Khare A, Raina R. Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure. Cardiol Res. 2017;8(3):87-95.Verma D, Firoz A, Garlapati SKP, Sai Charaan Reddy Sathi T, Haris M, et al. Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management. Cureus. 2021;13(8):e17240.Obi Y, Kim T, Kovesdy CP, Amin AN, Kalantar-Zadeh K. Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome. Cardiorenal Med. 2016;6(2):83-98.Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319-31.Aghel A, Tang WH. Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. Core Evid. 2008;3(1):31-43.Bielecka-Dabrowa A, Godoy B, Schefold JC, Koziolek M, Banach M, von Haehling S. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence? Curr Heart Fail Rep. 2018;15(4):224-238.Takahama H, Kitakaze M. Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. Am J Physiol Heart Circ Physiol. 2017;313(4):H715-H721.Testani JM, Coca SG, McCauley BD, Shannon RP, Kimmel SE. Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail. 2011;13(8):877-84.Takeuchi M, Nagai M, Dote K, Kato M, Oda N, Kunita E, et al. Early drop in systolic blood pressure, heart rate at admission, and their effects on worsening renal function in elderly patients with acute heart failure. BMC Cardiovasc Disord. 2020;20(1):366.Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41(6):997-1003.Mody BP, Khan MH, Zaid S, Ahn C, Lloji A, Aronow WS, et al. Survival With Continuous Outpatient Intravenous Inotrope Therapy in the Modern Era. Am J Ther. 2020;28(6):e621-e630.Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21(6):431-5.Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-91.Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jand;oacute;dar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19)1834-1844.Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422-34.Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117and;ndash;27.Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089and;ndash;98.Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Kand;oslash;ber L,and;nbsp; et al. Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation. 2022; 146(6):438-449.Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, et al. Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD. J Am Soc Nephrol. 2024;35(2):202and;ndash;15Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J. 2023;44(31):2966and;ndash;77.Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Monnerat S, et al. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2023;34(2):322-332.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099.Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 J;380(24):2295-2306.Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99.Kalra S, Aydin H, Sahay M, Ghosh S, Ruder S, Tiwaskar M, et al. Cardiorenal Syndrome in Type 2 Diabetes Mellitus - Rational Use of Sodium-glucose Cotransporter-2 Inhibitors. Eur Endocrinol. 2020;16(2):113-121.Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291-1298.Zelniker TA, Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(15):1845-55.Silva Dos Santos D, Polidoro JZ, Borges-Jand;uacute;nior FA, Girardi AC. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C328-C36.Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7)463-474.Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021 17(4)227-44.Nagahisa T, Saisho Y. Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Ther. 2019;10(5):1733-1752.Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023 ;20(7):463-474.Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225.Frand;iacute;as JP, Davies MJ, Rosenstock J, et al.Frand;iacute;as JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med.2021;385(6):503-515.Davis MK, Virani SA. Cardiac resynchronization therapy in the cardiorenal syndrome. Int J Nephrol. 2011;2011:168461.Singal G, Upadhyay GA, Borgquist R, Friedman DJ, Chatterjee NA, Kandala J, et al. Renal Response in Patients with Chronic Kidney Disease Predicts Outcome Following Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2015;38(10):1192-200.Garg N, Thomas G, Jackson G, Rickard J, Nally JV Jr, Tang WH, et al. Cardiac resynchronization therapy in CKD: a systematic review. Clin J Am Soc Nephrol. 2013;8(8):1293-303.Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J. 2011;32(2):184-90.Gallinoro E, Vanderheyden M, Bartunek J. Device-based therapy of acute cardiorenal syndrome in heart failure. Card Interv Today. 2021;15(3):38and;ndash;43.Rosenblum H, Kapur NK, Abraham WT, Udelson J, Itkin M, Uriel N, et al. Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRI2P2S. Circ Heart Fail. 2020;13(4):e006731.Nathan S, Basir M. Emerging Device Therapies for Cardiorenal Syndrome. JSCAI. 2023;2;101210.Beldhuis IE, Streng KW, van der Meer P, Ter Maaten JM, Oand;#39;Connor CM, Metra M, et al. Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. J Card Fail. 2019 ;25(11):866-874.de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, Clark AL, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006;27(5):569-81.Testani JM, McCauley BD, Chen J, Coca SG, Cappola TP, Kimmel SE. Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail. 2011 ;17(12):993-1000.Logeart D, Tabet JY, Hittinger L, Thabut G, Jourdain P, Maison P, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol. 2008;127(2):228-32.George LK, Koshy SKG, Molnar MZ, Thomas F, Lu JL, Kalantar-Zadeh K, et al. Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function. Circ Heart Fail 2017; 10(8):e003825.Testani JM, McCauley BD, Kimmel SE, Shannon RP. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. Am J Cardiol. 2010;106(12):1763-9.